Tumor News and Research

RSS

Study shows 95 percent of radiation oncologists use FDG-PET, MRI and 4DCT to locate cancer

A recent study shows that 95 percent of radiation oncologists use advanced imaging techniques such as positron emission tomography (FDG-PET), magnetic resonance imaging (MRI), and 4-dimensional computed tomography (4DCT) for target delineation (to locate the tumor and other areas at risk for having cancer), according to an article in the December issue of the Journal of the American College of Radiology, (JACR, www.jacr.org).

25 Nov 2009

New biodegradable drug-eluting fibers advance stent technology and brain surgery

Stents that keep weakened and flabby arteries from collapsing have been true life-savers. But after six months, those stents are no longer needed -- once the arteries are strengthened, they become unnecessary. Previously, doctors had no choice but to leave them in place.

25 Nov 2009

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

CytRx to initiate a multinational Phase 2 clinical trial of its doxorubicin prodrug

CytRx Corporation, a biopharmaceutical company, today announced plans to initiate a multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a treatment for patients with advanced soft tissue sarcomas who have failed surgery and radiation. Soft tissue sarcomas are cancers that are formed in the muscle, fat, fibrous tissue, blood vessels or other supporting tissue of the body.

24 Nov 2009

Delcath Systems sponsors "Regional Therapeutic Options for Metastatic Melanoma" symposium

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies by clinical leaders in the field.

24 Nov 2009

New finding reveals Barrett's esophagus in asymptomatic women undergoing endoscopic screening

In the November issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE), a study out of Stanford University found that Barrett's esophagus was detected in six percent of asymptomatic women undergoing endoscopic screening.

24 Nov 2009

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, and Clovis Oncology, Inc., the newly formed oncology company led by former Pharmion Corporation executives, announced today an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.

24 Nov 2009

Mutated IDH1 gene linked to the progression of gliomas

23 Nov 2009

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.

23 Nov 2009

AdnaTest BreastCancer Select & Detect kit now available in the Czech Republic and Slovakia

OncoVista Innovative Therapies, Inc., reported that the AdnaTest BreastCancer Select & Detect kit, manufactured by AdnaGen AG (Langenhagen, Germany), is now available for research as well as for pay-out-of-pocket patients in the Czech Republic and Slovakia.

23 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Fred Hutchinson Cancer Research Center has received a pledge of $10 million to advance the promising field of immunotherapy research to treat and cure cancer, even in late stages.

23 Nov 2009

Initiation of Phase I/IIa clinical trial of IL-7 announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa clinical trial of IL-7 in support of tumor lysate/KLH pulsed dendritic cell vaccines in a pilot study of tumor vaccination in patients with metastatic or recurrent pediatric solid tumors and altered T cell homeostasis, including patients with Ewing’s sarcoma family of tumors (ESFT), rhabdomyosarcoma, neuroblastoma, synovial cell sarcoma, desmoplastic small round cell tumor, undifferentiated sarcoma, and embryonal sarcoma.

23 Nov 2009

Winship-led team identifies a way to exploit cancer cells' taste for glucose

The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.

23 Nov 2009

BMI and co-morbidity do not explain racial survival disparity in colon cancer patients

A new study by University of Alabama at Birmingham (UAB) researchers shows that body-mass index (BMI) and co-existing medical conditions (co-morbidity) do not explain the decreased survival observed among African-Americans compared to Caucasians who also have colon cancer. The study is published online Nov. 23 in Cancer, a journal of the American Cancer Society.

23 Nov 2009

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. By exploiting this mechanism, researchers have been able to powerfully suppress tumor formation in lab testing and in animal models.

22 Nov 2009

Cancer promoting gene identified

Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Scientists hope the finding could lead to an effective therapy to target and inhibit the expression of this gene resulting in inhibition of cancer growth.

21 Nov 2009

Program on patients undergoing individualized treatment for metastatic breast cancer: NCCN

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, has collaborated with the Discovery Health Channel to produce a program profiling three patients with metastatic breast cancer and their healthcare team as they customize each patient's treatment regimen to their individual tumor type and health status.

21 Nov 2009

New hope for patients with liver cancer

In patients with unresectable (unable to be removed by surgery) liver cancer, an interventional radiology procedure called triple-drug transcatheter arterial chemoemobolization (TACE) followed by a liver transplant may significantly increase a patient's chance of long-term survival, according to a study published in the December issue of the American Journal of Roentgenology.

21 Nov 2009

Tumor News and Research

Study shows 95 percent of radiation oncologists use FDG-PET, MRI and 4DCT to locate cancer

New biodegradable drug-eluting fibers advance stent technology and brain surgery

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

CytRx to initiate a multinational Phase 2 clinical trial of its doxorubicin prodrug

Delcath Systems sponsors "Regional Therapeutic Options for Metastatic Melanoma" symposium

New finding reveals Barrett's esophagus in asymptomatic women undergoing endoscopic screening

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Mutated IDH1 gene linked to the progression of gliomas

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

AdnaTest BreastCancer Select & Detect kit now available in the Czech Republic and Slovakia

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Initiation of Phase I/IIa clinical trial of IL-7 announced

Winship-led team identifies a way to exploit cancer cells' taste for glucose

BMI and co-morbidity do not explain racial survival disparity in colon cancer patients

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Cancer promoting gene identified

Program on patients undergoing individualized treatment for metastatic breast cancer: NCCN

New hope for patients with liver cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News